Muckle-Wells Syndrome (MWS) is a
rare, genetic autosomal disease which leads to urticaria, sensorineural
deafness, and also leads to amyloidosis. The disease is mainly caused due to
mutation of CIAS1 gene, that leads to increased production of interleukin 1B.
Due to interaction of IL1B and skin receptors, the inflammation occurs, which
leads to fever and rashes. The common symptoms include fevers, chills,
deafness, arthritis, and recurrent urticaria.The episode of MWS usually lasts
for around 48 hours. The disease belongs to a family of cryopyrin- associated
periodic syndromes (CAPS), including 2 other diseases, caused by mutation of CIAS1
gene.
Visit Complete Report Here: http://www.marketresearchreports.biz/analysis-details/muckle-wells-syndrome-market-global-industry-analysis-size-share-growth-trends-and-forecast-2013-2019
Muckle-Wells Syndrome can be
diagnosed with the help of study of patient’s symptoms and medical evaluation.
In addition, gene testing and NLRP3 mutation study also helps in diagnosis of
the disease. Owing to extensive growth in genetic engineering, the market is
expected to grow duringthe forecast period 2013 to 2019. The major treatments
for MWS includes Rilonacept (for CAPS treatment), anakinra (IL-1 receptor
antagonist) and Canakinumab, a monoclonal antibody. In addition to the
existing treatments, some new treatments are under pipeline studies.
The market of Muckle-Wells Syndrome
is driven by factors such as, extensive R&D activities, technological
advancement in research and genetic sciences and growing concern about various
genetic disorders. Extensive R&D is one of the major factor, propelling
the market growth. Considering the growth perspective, many pharmaceutical and
biotechnological leaders are engaged in the development of medications and
treatments for this disease. However, low epidemiology, lack of awareness and
high cost of R&D and treatment are some of the restraints, expected to
impose a threat to the growth of the market.
Some of the major players engaged
in development and commercialization of treatments for Muckle-Wells Syndrome
includes Novartis AG, Istituto Giannina Gaslini, Regeneron Pharmaceuticals,
Inc. and Charite-Universitatsmedizin Berlin amongst others.
This research report analyzes this
market depending on its market segments, major geographies, and current market
trends. Geographies analyzed under this research report include
- North America
- Asia Pacific
- Europe
- Rest of the World
This report provides comprehensive
analysis of
- Market growth drivers
- Factors limiting market growth
- Current market trends
- Market structure
- Market projections for
upcoming years
This report is a complete study of
current trends in the market, industry growth drivers, and restraints. It
provides market projections for the coming years. It includes analysis of
recent developments in technology, Porter’s five force model analysis and
detailed profiles of top industry players. The report also includes a review
of micro and macro factors essential for the existing market players and new
entrants along with detailed value chain analysis.
Reasons for Buying this Report
- This report provides pin-point
analysis for changing competitive dynamics
- It provides a forward looking
perspective on different factors driving or restraining market growth
- It provides a technological
growth map over time to understand the industry growth rate
- It provides a seven-year
forecast assessed on the basis of how the market is predicted to
grow
- It helps in understanding the
key product segments and their future
- It provides pin point analysis
of changing competition dynamics and keeps you ahead of competitors
- It helps in making informed
business decisions by having complete insights of market and by making
in-depth analysis of market segments
- It provides distinctive
graphics and exemplified SWOT analysis of major market segments
Contact US: 
|
Office: United States
|
|
State Tower
90 State Street, Suite 700 Albany, NY 12207 United States |
